




What is COMPPARE?

COMPPARE stands for "A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE)." This study is funded by the Patient-Centered Outcomes Research Institute (PCORI) and led by Dr. Nancy Mendenhall at the University of Florida. COMPPARE will ask 3,000 prostate cancer patients (ages 30-80) across the US who have chosen to be treated with proton therapy or photon therapy to answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years.

In addition, proton therapy patients can choose to participate in a randomized trial in which half will be randomly assigned to the standard course of therapy and the other half will receive a shorter "hypofractionated" course in which the total dose of radiation will be divided into larger doses with fewer treatments. This additional study will evaluate whether quality of life, side effects, and cure rates differ between patients receiving standard therapy versus shorter therapy.



Where can I learn more about COMPPARE?

Visit <http://comppare.org> or email us at comppare-admin@ufl.edu.

Acknowledgement: Research reported in this brochure was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422).

Disclaimer: The statements presented in this brochure are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.

COMPPARE



**A Path to Improve Future Health Outcomes
for Men with Prostate Cancer**





Which radiation option is best?

Prostate cancer is the most common form of cancer (after skin cancer) for men in the US, with over 160,000 cases and 28,000 deaths occurring each year. Approximately one-third of all men with prostate cancer receive radiation therapy, which can cause short-term and long-term bowel and bladder damage that severely impacts quality of life. Most patients receive photon-based radiation therapy for prostate cancer; however, proton therapy is an alternative type of radiation that more precisely targets a tumor yet is also more expensive. Patients want to know which treatment option is best for them, but the effects of photons versus protons on quality of life, organ function, and prostate cancer cure rates have not been directly compared in a large, multi-institutional trial.



What is the goal of this study?

Our goal is to answer the following patient-centered questions:

1. How likely are men to experience different quality of life issues with protons versus photons?
2. How likely are men to experience different side effects with either treatment?
3. Which treatment will result in a better cure rate?
4. Is a shorter, higher dose treatment regimen as safe and effective as a longer, lower dose treatment regimen?

Because men of African descent are 1.6 times more likely to be diagnosed with prostate cancer and more than twice as likely to die from it, we will actively work to recruit Black men to this study and assess whether quality of life, side effects, and cancer recurrence outcomes differ for these patients.

What is the benefit of participating in this study?

Over the first 3 years of the study, you will receive up to \$250 for completing surveys before radiation begins, during treatment, and at follow-up visits. More importantly, by participating in COMPPARE, you will also be part of something bigger. You may help future patients make more informed treatment decisions regarding radiation therapy for their prostate cancer and potentially affect health care policy.



Why is this study important for patients?

This study will directly compare the potential benefits and harms of protons versus photons. It will emphasize patient-centered outcomes and help future patients make evidence-based treatment decisions. Moreover, as many insurers do not cover proton therapy for prostate cancer due to its higher cost and unanswered questions about its effectiveness compared to photon therapy, the study results will provide the data needed for coverage and policy decisions.

